1286650

氟维司群

United States Pharmacopeia (USP) Reference Standard

• 别名: (7α,17β)-7-[9-[(4,4,5,5,5-五氟戊基)亚磺酰基]壬基]雌-1,3,5(10)-三烯-3,17-二醇, ICI 182,780, ZD 182780, ZD 9238, ZM 182780, 与法洛德
• 经验公式（希尔记法）: C₃₂H₄₇F₅O₃S
• CAS号: 129453-61-8
• 分子量: 606.77
• MDL號碼: MFCD00903953
• 分類程式碼代碼: 41116107
• PubChem物質ID: 329749913
• NACRES: NA.24

属性

• 等級: pharmaceutical primary standard
• API 家族: fulvestrant
• 製造商／商標名: USP
• 應用: pharmaceutical (small molecule)
• 形式: neat
• 儲存溫度: 2-8°C
• SMILES 字串: [H][C@]12CC[C@]3(C)[C@@H](O)CC[C@@]3([H])[C@]1([H])[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)Cc4cc(O)ccc24
• InChI: 1S/C32H47F5O3S/c1-30-17-15-26-25-12-11-24(38)21-23(25)20-22(29(26)27(30)13-14-28(30)39)10-7-5-3-2-4-6-8-18-41(40)19-9-16-31(33,34)32(35,36)37/h11-12,21-22,26-29,38-39H,2-10,13-20H2,1H3/t22-,26-,27+,28+,29-,30+,41?/m1/s1
• InChI 密鑰: VWUXBMIQPBEWFH-WCCTWKNTSA-N
• 基因資訊: human ... ESR1(2099) , ESR2(2100)

说明

一般說明

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.
For further information and support please go to the website of the issuing Pharmacopoeia.

應用

• Targeted Radiation Drug for Breast Cancer: Fulvestrant was utilized in fluorocarbon nanoparticles combined with iodine-131, demonstrating potential as a targeted radiation drug for endocrine therapy in breast cancer treatment, enhancing the applicability of Fulvestrant in advanced therapeutic approaches (Zhi et al., 2024).


• Pharmacological Insights: A comprehensive review discussed novel oral selective estrogen receptor degraders, including Fulvestrant, detailing their mechanism and efficacy in breast cancer treatment, providing crucial insights for ongoing pharmaceutical research and development (Guglielmi et al., 2024).


• Quantification in Clinical Practice: Development of an LC-MS/MS method for the simultaneous quantification of four hormone therapy drugs, including Fulvestrant, in breast cancer patients supports its clinical application and monitoring, ensuring effective patient management and therapy optimization (Mansour et al., 2024).

生化／生理作用

氟维司群是一种选择性雌激素受体下调剂（SERD）；具有高亲和力的雌激素受体拮抗剂。

氟维司群（ICI 182,780）是一种选择性雌激素受体下调剂（SERD）。氟维司群是一种具有高亲和力的雌激素受体拮抗剂。IC₅₀ = 0.29 nM。氟维司群是第一种“纯”抗雌激素，在体外和体内均无激动活性。

分析報告

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

其他說明

Sales restrictions may apply.

安全信息

• 象形圖: GHS08,GHS09
• 訊號詞: Danger
• 危險聲明: H360Df,H362,H410
• 防範說明: P202 - P260 - P263 - P264 - P273 - P308 + P313
• 危險分類: Aquatic Chronic 1 - Lact. - Repr. 1B
• 儲存類別代碼: 6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
• 水污染物質分類（WGK）: WGK 3
• 閃點（°F）: Not applicable
• 閃點（°C）: Not applicable